Tag Archives: Zymergen

Synthetic Biology Firm Ginkgo Bioworks Acquires DNA Synthesis Provider Gen9

Recently, Ginkgo Bioworks (client registration required) announced the acquisition of DNA synthesis provider Gen9 (client registration required) for an undisclosed amount of cash and stock. Ginkgo will integrate into its existing Bioworks facilities Gen9’s BioFab platform, which includes its chip-based oligo synthesis process, Agilent Technologies’ Oligonucleotide Library Synthesis (OLS) pool, and proprietary software/informatic tools for DNA design and error correction. Along with all related equipment and intellectual property (IP) of up to 125 patents pending, the acquisition also includes Gen9’s full-time staff on production and R&D, but not the management, sales, and customer service teams. Continue reading

2016 BBMC Roundup and What You Can’t Miss Going Into 2017

2016 was a turning point for the bio-based materials and chemicals (BBMC) space as the industry realigned to sustained low oil prices, shifting consumer demand, and emerging regulatory drivers. In our latest report, we highlight the big bets investors placed in 2016 (client registration required). To emphasize these trends, we round-up some of the major announcements throughout the year and summarize them into the three key themes outlined below: Continue reading

Synthetic Biology Advances With Robotics and Machine Learning

Synthetic biology (“synbio”) initially attracted high-profile venture capitalists and corporate partnerships for its products – bio-based chemicals and alternative fuels, for example. Today, synbio companies tools are attracting attention as well – from lab automation like DNA synthesis-as-a-service, to software (i.e. BioCAD and BioLIMS), and new genetic engineering tools (i.e. CRISPR). By integrating machine-learning, robotics, and high-throughput engineering, companies like Ginkgo Bioworks and Zymergen are helping customers dramatically reduce the timeline for developing new molecules in the flavor and fragrance, food ingredient, medical, agricultural, and specialty chemicals markets – a key reason that those two startups each raised more than $100 million in 2016. This podcast highlights Lux’s thoughts on the impact of these tools in and beyond in synbio, and the rapidly developing ecosystem of startups within the space.

To listen to the podcast, click here.

By: Mark Bünger and Victor Oh